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Pretherapeutic identification of oesophageal squamous cell carcinomas that will respond to neoadjuvant chemoradiotherapy is an
important attempt for improvement of patient’s prognosis. In the current study, pretherapeutic biopsies from 94 oesophageal
squamous cell carcinomas (cT3, cN0/þ, cM0) in patients who underwent neoadjuvant chemoradiotherapy (RCTx: 45Gy plus
cisplatin and 5-fluorouracil) and subsequent oesophagectomy in the setting of a single-centre prospective treatment trial were
investigated by means of immunohistochemistry. Expression of proteins involved in DNA repair and/or cell-cycle regulation, that is
p53, p53 (phosphorylated at Ser15), EGFR, ATM protein kinase (phosphorylated at Ser1981) and checkpoint kinase 2 (CHK2)
(phosphorylated at Thr68) was correlated with the response to RCTx and with overall survival. Tumours that were positive for
CHK2 expression more frequently showed clinically determined regression after RCTx (69.4%) than tumours that were negative for
CHK2 expression (32.1%; P¼0.0011), whereas other parameters did not correlate with tumour regression. Expression of ATM
correlated with expression of CHK2 (P¼0.0061) and p53-phospho (P¼0.0064). Expression of p53 correlated with expression of
p53-phospho (Po0.0001). In contrast to clinical and histopathological response evaluation, none of the molecular parameters under
investigation correlated with overall survival. In conclusion, expression analysis of p53, EGFR CHK2 and ATM has no predictive value
in multimodally treated oesophageal squamous cell carcinoma.
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The prognosis for patients with oesophageal squamous cell
carcinoma has only improved slightly in recent years. The results
of surgical therapy have been poor, with 5-year survival rates
varying between 9 and 40%, even with lesions in resectable stages
(Enzinger and Mayer, 2003). Combined treatment modalities –
including chemotherapy, radiotherapy and surgical treatment – have
therefore been investigated in increasing number of studies to
improve the survival of patients with oesophageal cancer. These
studies have indicated a complete response in 20–40% of patients
preoperatively treated with combined radiotherapy and chemo-
therapy (Ilson, 2004). However, with regard to survival, the
benefit of combined neoadjuvant treatment modalities has
only been confirmed unequivocally in the subset of patients
who have a complete response at histopathological examination
(Lerut et al, 1999; Ancona et al, 2001; Bru ¨cher et al, 2004).
Finding parameters that might help identify those patients
capable of benefiting from multimodal treatment modalities before
the start of therapy would therefore be of considerable interest
(Lerut et al, 1999; Ilson, 2004).
In the present study, an immunohistochemical assessment was
therefore carried out of the expression of a panel of genes (p53,
EGFR, ATM and CHK2) that are potentially involved in the
response to chemoradiotherapy. Expression analysis was based on
pretherapeutic tumour biopsies from 94 patients who had locally
advanced oesophageal squamous cell carcinoma and received
multimodal treatment. Subsequently, protein expression was




All of the patients included in the present investigation were
participants in prospective single-centre phase II studies con-
ducted at the Rechts der Isar Hospital, Technical University of
Munich, Germany. The results of these studies, together with
the criteria for patient selection and study design, have been
previously described elsewhere (Bru ¨cher et al, 2004). Patients who
had previously undergone chemotherapy, radiotherapy, laser
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stherapy or stent implantation were excluded from this study.
Informed consent was obtained from all patients.
Patients with histologically proven, locally advanced intra-
thoracic (n¼81) or cervical (n¼13) oesophageal squamous cell
cancer, without distant metastases (uT3, uN0/þ, cM0), who were
considered medically fit for surgery were treated with neoadjuvant
chemoradiotherapy (Bru ¨cher et al, 2004) in consecutive phase II
trials between 1999 and 2004, followed by oesophagectomy. The
staging procedures in all patients consisted of endoscopy,
endoluminal ultrasonography (EUS), bronchoscopy (including
brush cytology and biopsy) and computed tomography.
Neoadjuvant chemoradiotherapy and clinical response
evaluation
The neoadjuvant regimen consisted of simultaneous radiotherapy/
chemotherapy. External-beam radiotherapy was delivered using a
two-opposed-field technique with 10 or 15MV photons (Siemens
Mevatron KD-2) at 2Gy per fraction per day, five fractions per
week, up to the year 2000. Between 1999 and 2000, the total dose
was 40Gy (Bru ¨cher et al, 2004). The clinical target volume, which
initially included all of the locoregional lymph-node stations in
addition to the tumour, was modified and reduced to the directly
juxtaregional nodes (tumour±4cm craniocaudally), extended by
1.5cm in all directions for the planning target volume, taking
patient movements into account. The total dose was increased
thereafter to 45Gy using single doses of 1.8Gy. From this time on,
three-dimensional treatment planning with three- to five-field
conformal techniques was used. Between 1999 and 2000, 5-
fluorouracil at 300mgm
 2/day was administered simultaneously
with radiotherapy as a continuous infusion for 21 days by means of
a systemic venous port system. Between 2000 and 2003, cisplatin
(CDDP) was administered in addition to 5-fluorouracil five times
weekly in weeks 1 and 5, at a dosage of 20mgm
 2. As of 2003,
patients were enrolled in a phase I/II dose-finding study in which
oxaliplatin 40–50mgm
 2, administered once weekly, replaced
CDDP. The dosage of 5-fluorouracil was reduced to 225mgm
 2
per day, given as a continuous infusion. No significant impact
on clinical outcome was detectable in relation to differences of
neoadjuvant therapy protocols (data not shown).
All of the patients underwent clinical response evaluation as
described in detail earlier. Briefly, clinical response evaluation was
carried out 3–4 weeks after completion of multimodal therapy,
using repeated endoscopy and computed tomography in accor-
dance with the World Health Organization criteria (Miller et al,
1981). In detail, response as assessed by endoscopy was
determined by one investigator. Categorisation was based on
macroscopic aspects of the intra-luminal tumour mass. Endoluminal
ultrasonography had not been used for clinical response evalua-
tion, since own experiences have shown lack of diagnostic accuracy
after radiochemotherapy (Bru ¨cher et al. 2004). Additionally,
response assessment according to the computed tomography scan
was performed by one experienced radiologist, measuring maximal
tumour length and maximum wall thickness before and after
treatment. Clinical findings as well as the results of endoscopy and
radiology were discussed by the investigators and response was
defined in consensus according to the WHO criteria: clinical
complete response, clinical partial response, clinical minimal
response and clinical no change. For statistical analysis, the clinical
response was divided into two groups: group 1 (clinical responder)
consisted of patients with clinical complete response and clinical
partial response, while group 2 (clinical nonresponder) included
patients with clinical minimal response and clinical no change.
Surgical therapy
Surgery was performed on all patients within 1 week after the
clinical response evaluation. The patients underwent standardised
transthoracic en bloc oesophagectomy with two-field lymphade-
nectomy (Siewert et al, 2001). Gastrointestinal continuity was
restored with a two-stage gastric pull-up procedure, as described
previously (Bru ¨cher et al, 2006). To avoid a high rate of paresis of
the recurrent nerves, lymph-node dissection in the neck was
not performed. Cervical tumours were treated with a partial
oesophageal resection and reconstructed with a free jejunal graft
(Bru ¨cher et al, 2007).
Histopathological response evaluation
The resection specimens were fixed in formaldehyde (4%) for 24h.
The complete tumour was embedded in paraffin blocks. Sections
of each paraffin block were cut (5mm) and stained with
haematoxylin and eosin. The tumour stage was classified in
accordance with the UICC criteria (Wittekind et al, 2002).
Accordingly, 34 tumours were categorised ypT0, 7 ypT1, 23
ypT2, 28 ypT3 and 2 ypT4. Regarding nodal status, 62 tumours
were in category ypN0 and 32 in ypN1. The histopathological
response to chemoradiotherapy was classified in accordance with
criteria published previously (Becker et al, 2003; Bru ¨cher et al,
2006). The percentage of viable residual tumour cells was
estimated, and individual patients were subsequently allocated to
one of the following groups: no residual tumour cells; o10%
residual tumour cells/tumour area; 10–50% residual tumour cells;
and 450% residual tumour cells.
Pathological review of pretherapeutic tumour biopsies
The tumour biopsies obtained endoscopically during the prether-
apeutic staging procedures were retrieved from the files of the
Institute of Pathology at the Technical University of Munich,
with approval from the local ethics committee. Of the 94 patients,
71 were male and 23 were female. Their median age was 59 years
(range, 19–76). Histological slides of the biopsy specimens were
stained with haematoxylin and eosin to determine the tumour type
and tumour grade (WHO) by one of the authors (MS). Thirty-two
tumours were graded as G2 and 62 tumours were graded as G3.
Immunohistochemical investigations based on
pretherapeutic tumour biopsies
Fresh 4-mm sections from the pretherapeutic biopsies were
transferred to glass slides, dewaxed and rehydrated. Antigen
retrieval methods (e.g., microwave oven heating in citrate-buffered
saline) were used in accordance with the manufacturers’ recom-
mendations. Subsequently, the slides were incubated with the
primary antibodies. Detailed data on the antibodies are given in
Table 1. For three of the four proteins being analysed – that is, p53,
ATM, and CHK2 – antibodies were used that detect phosphoryla-
tion at specific amino-acid residues that indicate functional
activity (ATM, CHK2) (Bakkenist and Kastan 2003; Bartkova
et al, 2005) or resistance against inactivation (p53) (Shieh et al,
1997). The reaction was developed using the labelled streptavidin–
biotin–alkaline phosphatase system, with fast red as chromogen.
After counterstaining with haematoxylin, the slides were dehy-
drated in increasing concentrations of ethanol and mounted. For
positive controls, tissues with known expression of the respective
antigens were used (p53 and EGFR: oesophageal squamous cell
carcinoma; ATM and CHK2: colorectal carcinoma). For negative
controls, irrelevant antibodies with the same immunoglobulin
isotype were used.
The slides were reviewed by a single pathologist (MS) who was
blinded to the results of chemoradiotherapy and the patients’
survival data. In an initial approach, the percentage of immuno-
reactive tumour cells was graded on a scale of 0–4 (0¼0–4%
positive tumour cells; 1¼5–24%; 2¼25–49%; 3¼50–74%;
4¼75–100%). Subsequent correlation analyses – including
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smolecular markers, tumour regression following chemoradio-
therapy and overall survival – revealed small groups of patients
who were unsuitable for meaningful statistical analysis. None of
the statistical analyses showed significant correlations (data not
shown). All of the molecular markers were therefore subsequently
analysed as binary variables (negative vs positive).
Follow-up
After resection, the patients were examined every 3 months for 2
years at the outpatient clinic, and thereafter at 6-monthly intervals.
Follow-up included a physical examination, laboratory investiga-
tions, plain chest radiography, upper gastrointestinal endoscopy,
abdominal ultrasound and computed tomography of the chest
and abdomen. Immobilised patients with low performance status
were examined for progress and/or recurrence by their general
practitioner. The follow-up was complete, with a median of
5.0±1.5 years (95% CI, 2.3–7.3). Thirty-six of the 94 patients
(38.3%) died during the follow-up period.
Statistical analysis
The SAS software package (SAS Institute Inc., Cary, NC, USA) was
used for statistical analysis. Statistical analysis of the correlation
between therapy-induced tumour regression and molecular
markers (p53, EGFR, ATM, CHK2) was carried out using the
two-tailed Fisher’s exact test. The parameters were dichotomised
as follows: tumour response, o10% residual tumour cells vs
X10% residual tumour cells; molecular markers were dichoto-
mised as negative vs positive. The Kaplan–Meier method for
analysing censored data was used to calculate survival rates and
tested with the log–rank test. Probabilities o0.05 were considered
statistically significant.
RESULTS
Clinical and histopathological response after neodjuvant
radiochemotherapy
Following completion of neoadjuvant radiochemotherapy,
according to clinical response evaluation, 53 cases showed partial
response, 40 showed minimal response and 1 showed no change.
According to histopathological response evaluation, 34 cases
showed no residual tumour cells (complete response), 26 showed
o10% residual tumour cells (major response), 23 showed 10–50%
residual tumour cells (partial response) and 11 showed 450%
residual tumour cells (minor response/no change).
Immunohistochemical analyses of pretherapeutic tumour
biopsies
Nuclear accumulation of p53 protein was found in 77.8% of the
cases, and nuclear accumulation of p53 protein, phosphorylated at
Ser15, was detectable in 73.3% of the cases. Concordance (either
both positive or both negative) between p53 and p53 (phospho-
Ser15) was found in 69 cases (82.1%), whereas discordance was
present only in 15 cases (17.9%; Po0.0001). In addition,
expression of p53-phospho correlated with expression of ATM
(concordance: 76.3%; P¼0.0064). Neither the expression of p53
nor of p53 (phospho-Ser15) correlated with any of the other
markers under analysis (data not shown).
Nuclear expression of ATM was found in 91.6% of the tumours,
whereas nuclear expression of CHK2 was detected in 66.7% of
cases. Concordance between ATM and CHK2 was found in 55 cases
(72.4%), whereas discordance was present only in 21 cases (27.6%;
P¼0.0061). Expression of neither ATM nor CHK2 correlated with
any of the other markers under analysis (data not shown).
Expression of EGFR at the cytoplasmic membrane was detected
in 98.9% of tumours, with only one tumour being negative for
EGFR expression. No correlation was found between EGFR
expression and the expression of any of the other markers.
Correlation between molecular markers and tumour
regression after chemoradiotherapy
Complete or partial tumour regression after chemoradiotherapy,
as determined by the clinical follow-up, was observed in 69.6%
of the tumours that were positive for CHK2 expression, but only
in 32.1% of tumours that were negative for CHK2 expression
(P¼0.011). No correlation was found between clinically deter-
mined tumour regression and the expression of the other
parameters under investigation (Table 2). In addition, no
Table 1 Antibodies used in this study
Marker Clone Company Dilution Buffer, antigen retrieval
p53 DO-7 Dako, Hamburg, Germany 1:200 Citrate, pH 6; heating 7min
p53, phosphorylated at Ser15 3A36 United States Biological, Swampscott, MA, USA 1:75 Citrate, pH 6; heating 7min
EGFR 31 G7 Cytomed, Baden-Baden, Germany 1:60 Protease, 20min
ATM, phosphorylated at Ser1981 7C10D8 Rockland, Gilbertsville, PA, USA 1:1500 Citrate, pH 6; heating 7min
CHK2, phosphorylated at Thr68 Cat. No. 2661S Cell Signaling Technology, Danvers, MA, USA 1:200 Citrate, pH 6; heating 7min
Table 2 Correlation between the immunohistochemically determined
parameters and clinically determined tumour regression following poly-








Negative 10 (50) 10 (50) NS
Positive 39 (55.7) 31 (44.3)
p53 (phospho)
Negative 12 (52.2) 11 (47.8) NS
Positive 38 (60.0) 25 (40.0)
EGFR
Negative 0 (0) 1 (100) NS
Positive 49 (56.3) 38 (43.7)
ATM
Negative 4 (57.1) 3 (42.9) NS
Positive 43 (56.6) 33 (43.4)
CHK2
Negative 9 (32.1) 19 (67.9) P¼0.011
Positive 39 (69.6) 17 (30.4)
NS, no significant correlations according to the w
2-test.
aFor technical reasons (e.g.,
loss of tissue during immunohistological staining procedures), the number of cases
analysable for immunohistochemical analyses may differ from the total number of
cases under analysis.
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scorrelation was detected between histopathologically determined
tumour regression and marker expression (Table 3).
Survival analyses
No correlation was detectable between survival and the expression
of the parameters under analysis (Table 4). In contrast, clinical
response evaluation (P¼0.0254) as well as histopathological
response evaluation (Po0.0001) was significantly correlated with
overall survival.
DISCUSSION
The current study is based on the outcomes of the clinically and
pathologically determined response to chemoradiotherapy and
overall survival in patients with locally advanced oesophageal
squamous cell carcinoma, who were included in single-centre trials
conducted at the Technical University of Munich, Germany,
between 1999 and 2004. These major determinants of the results of
therapy were correlated with the expression of a panel of proteins
mainly involved in cell-cycle regulation and DNA repair.
Two of these molecules, p53 and EGFR, have been tested
previously as predictive markers for multimodally treated
oesophageal cancer. However, the results have been equivocal.
Thus, whereas some studies have indicated that p53 gene mutation
and/or p53 protein accumulation in tumour cells may be
significantly associated with resistance to multimodal therapy
and/or poor survival (Seitz et al, 1995; Ribeiro et al, 1998; Sarbia
et al, 1998; Krasna et al, 1999; Gibson et al, 2003), others have not
found such a correlation (Soontrapornchai et al, 1999; Ito et al,
2001; Shimada et al, 2002; Pu ¨hringer-Oppermann et al, 2006). With
regard to EGFR, two studies indicated that tumours with strong
EGFR expression show a relatively poor response to chemo-
radiotherapy (Hickey et al, 1994; Gibson et al, 2003), whereas
another study did not find such a correlation (Miyazono
et al, 2004). Moreover, in one of the two positive studies (Gibson
et al, 2003), EGFR was found to have predictive value in
oesophageal adenocarcinoma, but not in squamous cell carcinoma.
There may be many reasons for such discrepancies, but two
factors appear to be of particular importance – small sample sizes
and inhomogeneous patient selection. With regard to the sample
size, it should be noted that all but one (Soontrapornchai et al,
1999) of the investigations cited above included less than 100
patients in the analysis; the great majority of studies included even
less than 50 patients. With regard to patient selection, it is clear
that in most studies, patients were treated using a variety of
different treatment schedules. In addition, oesophageal adeno-
carcinomas and squamous cell carcinomas – and even carcinomas
of the gastro-oesophageal junction – are often lumped together in
clinical trials, although it is considered that important differences
with regard to molecular and clinical background as well as
to responsiveness to chemoradiotherapy between these tumour
types exist.
An attempt was made in the current study to overcome these
obstacles, at least partially. For example, a relatively large number
of patients (n¼94) was included, who were selected using
homogeneous criteria (including only one tumour type) and
treated with a current potentially curative treatment regimen.
However, the study clearly failed to show any significant predictive
value for the immunohistochemical evaluation of p53 and EGFR.
In the case of EGFR, this result is explained by the fact that a nearly
100% positivity rate was found in the biopsy material, so that it
was not possible to define prognostic subgroups of a reasonable
size. In the case of p53, largely identical results were found when
applying the standard antibody (DO-7) for detecting accumulated
p53 protein in formalin-fixed tissues and applying a relatively new
antibody that detects only p53 that is phosphorylated at Ser15.
The latter molecular modification has previously been shown to
confer protection to p53 against degradation by Mdm2 and thereby
to interfere with the radiosensitivity and/or chemosensitivity of
tumour cells (Shieh et al, 1997; Gao et al, 1999).
Somewhat more promising were the results concerning the other
two molecules analysed – that is ATM and CHK2. ATM, the gene
that is mutated in the hereditary disease ataxia-telangiectasia,
codes for a protein kinase that acts as a master regulator of cellular
responses to DNA double-strand breaks (Bakkenist and Kastan,
2003). ATM is activated in the event of DNA damage – for example,
Table 3 Correlation between the immunohistochemically determined
parameters and tumour regression as determined by histopathological
examination following chemoradiotherapy in 94 patients with multimodally








b 13 (65) 7 (35)
Positive 45 (64.3) 25 (35.7)
p53 (phospho)
Negative 12 (52.2) 11 (47.8)
positive 41 (65.1) 22 (34.9)
EGFR
Negative 1 (100) 0 (0)
Positive 55 (63.2) 32 (36.8)
ATM
Negative 5 (71.4) 2 (28.6)
Positive 49 (64.5) 27 (35.5)
CHK2
Negative 17 (60.7) 11 (39.3)
Positive 39 (69.6) 17 (30.4)
aNo significant correlations according to the w
2-test.
bFor technical reasons (e.g., loss
of tissue during immunohistological staining procedures), the number of cases
analysable for immunohistochemical analyses may differ from the total number of
cases under analysis.
Table 4 Correlation between immunohistochemically determined
parameters and overall survival in patients with multimodally treated











Negative 21 12 2.7
Positive 70 43 2.6
p53 (phospho) NS
Negative 23 13 1.9
Positive 64 39 2.5
EGFR NS
Negative 1 1 —
Positive 88 52 2.7
ATM NS
Negative 7 4 1.1
Positive 77 47 2.5
CHK2 NS
Negative 28 14 2.7
Positive 57 38 1.6
aAccording to the log–rank test. NS, not significant.
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sdue to exposure to ionising radiation. Several substrates of ATM
kinase are involved in radiation-induced cell-cycle arrest at the G1
checkpoint, – for example, p53, Mdm2 and CHK2. Moreover,
constitutive activation of ATM and CHK2 has recently been
demonstrated in a subset of malignant tumours (Bartkova et al,
2005). It is therefore tempting to speculate that the activation
status of ATM and CHK2 may significantly interfere with the
radiosensitivity and/or chemosensitivity of tumour cells (Kastan
and Bartek, 2004). However, this hypothesis has not yet been tested
clinically in patients with oesophageal cancer. Although a certain
degree of correlation was found between the expression of CHK2
and clinically determined tumour regression following chemo-
radiotherapy, this result largely disappeared when the expression
of CHK2 was correlated with the histopathologically determined
tumour regression. Since tumour regression can be determined
much more exactly by histopathological examination than by
clinical methods (Bru ¨cher et al, 2006), the predictive value of
CHK2 expression must be regarded with considerable scepticism.
Concerning the potential predictive value of ATM, no impact on
tumour regression or overall survival was detectable.
In conclusion, immunohistochemical analysis of the expression
of a panel of proteins in pretherapeutic biopsies from a relatively
large series of patients with multimodally treated, locally advanced
oesophageal squamous cell carcinoma did not reveal unequivocal
predictive markers. Additional studies in this field are warranted
to allow better identification of those patients who could be
benefiting from neoadjuvant therapy for this tumour type.
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